HT-29
Human colon cancer cell line
Overview
HT-29 is a human colorectal adenocarcinoma cell line that is widely used in cancer research. It was originally derived from a primary tumor of a 44-year-old Caucasian female. HT-29 cells are known for their ability to differentiate into enterocyte-like cells under certain conditions, making them a valuable model for studying intestinal epithelial cell biology and cancer.
Characteristics
HT-29 cells are epithelial in nature and exhibit a polygonal shape. They grow as a monolayer and have a doubling time of approximately 24 hours under optimal conditions. These cells are adherent and require a surface to attach to for growth. HT-29 cells are known for their high degree of aneuploidy, which is a common feature in cancer cells.
Growth Conditions
HT-29 cells are typically cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics such as penicillin and streptomycin. They are maintained at 37°C in a humidified atmosphere containing 5% carbon dioxide.
Differentiation
Under specific conditions, such as the presence of sodium butyrate, HT-29 cells can differentiate into cells that resemble mature intestinal epithelial cells. This property is utilized in studies investigating intestinal absorption, barrier function, and the effects of various compounds on intestinal health.
Applications in Research
HT-29 cells are extensively used in cancer research to study the mechanisms of colorectal cancer progression and to test potential therapeutic agents. They serve as a model for understanding the biology of intestinal epithelial cells and the processes of differentiation and tumorigenesis.
Drug Testing
Due to their human origin and cancerous nature, HT-29 cells are frequently used in drug screening assays to evaluate the efficacy and toxicity of new anticancer drugs. Researchers can assess the impact of these drugs on cell proliferation, apoptosis, and other cellular processes.
Molecular Studies
HT-29 cells are also employed in molecular biology studies to investigate gene expression, signal transduction pathways, and the role of specific genes in cancer development. Techniques such as CRISPR-Cas9 gene editing and RNA interference are often used to manipulate gene expression in these cells.
Limitations
While HT-29 cells provide a useful model for studying colorectal cancer, they have limitations. As a cell line, they may not fully recapitulate the complexity of human tumors in vivo. Additionally, their genetic and phenotypic characteristics can change over time with continuous passaging, which may affect experimental outcomes.
Related pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD